Co-vaccination with HA + F or conjugated HA-F enhanced anti-HA immunity (higher ELISA titers vs. HA alone); reduced lung viral burden for both influenza (X31, PR8) and RSV (A2) upon challenge; F acts as molecular adjuvant via TLR4; no vaccine-enhanced disease. This evidence concerns the gene TLR4 and influenza.